Next-generation respiratory medtech.
Dosehost is building SmartOx: intelligent oxygen therapy technology that adapts to each patient at home, grounded in peer-reviewed clinical research.
Built by respiratory experts and engineers.
Home oxygen is a blind spot in COPD care.
More than a million Americans rely on oxygen at home, yet what happens between clinic visits is largely unseen. The cost of that gap shows up in the hospital.
How a patient ends up back in the hospital.
Three things happen between the last clinic visit and the next admission.
Drops go unseen at home.
Patients on home oxygen can fall below safe oxygen levels during ordinary daily activity. A resting check in clinic will not catch it.
The clinic finds out late.
Clinicians usually learn how a patient is doing at the next scheduled visit, or once something has already gone wrong.
Exacerbations are ~50% more likely.
Patients who desaturate during a walking test were about 50% more likely to have had an exacerbation in the past year, the kind that sends a patient back to the hospital.
Cohort of 1,789 patients · International Journal of COPD, 2025
Better outcomes, less burden.
SmartOx is Dosehost's confidential medical-device program: intelligent technology that adapts home oxygen therapy to each patient. Technical specifications, design, and engineering details are not published.
A better quality of life
Designed to keep patients safely oxygenated through the demands of daily life, with less worry and more independence.
Lower desaturation risk
Built to reduce the dangerous oxygen drops that drive COPD exacerbations and avoidable hospital visits.
Less daily burden
A simpler home-oxygen experience for patients and caregivers: less to manage, fewer things to get wrong.
Backed by peer-reviewed research.
Published trials and meta-analyses in COPD oxygen therapy point the same way: patients walk further, breathe easier, and spend more time in a safe oxygen range.
Patient outcomes from peer-reviewed clinical research. Full citations available on request.
3 in 4 specialists are not confident their patients use oxygen as prescribed.
From a 2026 survey of 30 US pulmonary specialists and practice staff, fielded by MaRS.
More findings are in the evidence brief, sent to qualified organizations on request.
Built with healthcare organizations.
We're engaging a small group of qualified organizations across home respiratory care as the program develops.
Clinical practices and care organizations
Physician practices, respiratory and rehab groups, and care-management organizations looking to bring smarter oxygen therapy into their programs.
Home oxygen providers
DMEs and HMEs that want to offer patients a more modern oxygen experience, through a simple service relationship with no capital at risk.
Health systems and clinical partners
Organizations focused on COPD and respiratory outcomes that want early visibility into what we're building.
The SmartOx program is in active development. It is not yet available for commercial deployment.
Detailed information is shared only with qualified healthcare partners under a mutual non-disclosure agreement, following a short screening conversation.